News / Press Release

Early DMPK Analysis Means Opportunity for Better Results

October 25, 2018
Don’t skip important steps in preclinical research: drug metabolism and pharmacokinetic analysis (DMPK).

DMPK Quick Tips

More and more, researchers have seen that DMPK studies conducted sooner, rather than later, avoids moving forward compounds that may fail in later development. Build your preclinical work around smarter, more effective DMPK parameters with these tips:

1) Run DMPK analysis earlier.

DMPK analysis directly contributes to reduced drug attrition later in drug development. For optimal results, run DMPK studies as early as possible within your drug testing funnel. This can help you evaluate whether or not the compound has fundamental metabolic or pharmacokinetic liabilities that could limit future development.

2) Find the right assay.

Among parameters such as metabolism, permeability, protein binding or more, ample options await researchers as they employ the right mix of high-throughput assays for DMPK studies. To find yours, assess your study goals and align selected DMPK assays with your preclinical strategy.

3) Evolve for new advancements.

As new drug classes and targets emerge, account for those advancements with adjustments to DMPK parameters to ensure that important factors like additive toxicity or drug-drug interactions don’t go untested.

About Translational Drug Development (TD2)

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

About TD2

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

Contact
Tara Franks
602-358-8322
Get free tips, tools and resources by subscribing to the TD2 Newsletter: